Maria Grazia Valsecchi

Author

Also Known As

Anita Andreano, Chiara Gandossi, Claudia Toro, Giacomo Bellani, Giuseppe Foti, Leila Ronceray, M G Valsecchi, M Grazia Valsecchi, M Valsecchi, M. G. Valsecchi

458

Publications

22.5K

Citations

H-Index

159

Concepts

All Affiliations

University of Milano-Bicocca Azienda Ospedaliera San Gerardo University of Padua Istituti di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital

About

Maria Grazia Valsecchi is an author at University of Milano-Bicocca specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	55	4.3K
2	Public Health	12	12	1K
3	Health Sciences	8	8	620
4	Nursing	2	2	46
5	Arts	1	1	87

Maria Grazia Valsecchi

208

Publications

16.1K

Citations

H-Index

Page 1

	Year	Citations
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Valentino Conter, Claus R. Bartram, Maria Grazia Valsecchi, Blood	2010	778
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial Rob Pieters, Martin Schrappe, Paola De Lorenzo, The Lancet Hematological MalignancyAcute Lymphoblastic LeukaemiaOncologyPediatric EpidemiologyPediatric Hematology	2007	644
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study Martin Schrappe, Maria Grazia Valsecchi, Claus R. Bartram, Blood	2011	431
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon, JNCI Journal of the National Cancer Institute	2011	424
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia T Flohr, André Schrauder, Giovanni Cazzaniga, Leukemia Hematological MalignancyLymphoid NeoplasiaMedicineMixed-phenotype Acute LeukemiaMalignant Blood Disorder	2008	357
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study Andrea Biondi, Martin Schrappe, Paola De Lorenzo, The Lancet Oncology	2012	328
Incidence and Clinical Relevance of TEL/AML1 Fusion Genes in Children With Acute Lymphoblastic Leukemia Enrolled in the German and Italian Multicenter Therapy Trials Arndt Borkhardt, Giovanni Cazzaniga, Susanne Viehmann, Blood	1997	320
Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow Giuseppe Basso, Marinella Veltroni, Maria Grazia Valsecchi, Journal of Clinical Oncology	2009	287
<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Martin Stanulla, Elif Dağdan, Markéta Žaliová, Journal of Clinical Oncology	2018	285
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study Rob Pieters, Paola De Lorenzo, Philip Ancliffe, Journal of Clinical Oncology	2019	281

Page 1